Without our health, we have nothing. That’s why the health sector has always been one of our economy’s most resilient sectors. If there’s a product that enhances our health, there will be endless demand for it. And if there’s a treatment that manages/cures a debilitating condition, there is no price that affected parties won’t pay.

Because of this, you can make serious bank picking winning health stocks. But not all of these equities are accessible – once they rise above 10.00/share, it can be tough to build a significant position.

But not all is lost – you can buy up significant quantities of micro caps (or penny stocks) at affordable prices. In this post, we’ll talk about three health stocks that could surge in 2021 or beyond. Let’s get started.

Healthier Choices Management (OTCMKTS: HCMC)

If you smoke, you already know that it’s bad for you. But you also know that nicotine makes quitting cigarettes insanely difficult. No really – according to the American Heart Association, nicotine is just as addictive as cocaine or heroin.

No wonder we soon return to hacking darts after quitting for the 12th time. But there’s hope, as smokeless products (like those offered by HCMC) remove virtually all the harmful chemicals typically found in cigarettes.

In their vape stores, Healthier Choices Management sells e-cigs/e-liquid. While the latter does contain nicotine, the removal of carcinogens gives the user the time they need to quit – if they choose to do so, that is.

HCMC is also well-positioned to profit from an increase in health consciousness. This holding company owns several health & nutrition stores, as well as an organic market. From vitamins to antibiotic-free meat, they have much to offer their customers.

But an ongoing lawsuit with giant Phillip Morris offers the greatest short-term profit potential. Currently, HCMC holds patents and IP on many vaping technologies. Based on this, they allege that Phillip Morris violated these when they released IQOS, a smokeless tobacco product.

If Phillip Morris loses, they may have to pay a significant amount in damages. There are no numbers attached to this case, but on average, the average plaintiff spends 2.3 to 4 million USD on legal fees. Knowing this, the potential settlement will likely be much higher than that.

Currently, HCMC stock trades at 0.001. It’s an extremely affordable play, but also extremely risky – remember, this firm is nothing more than a holding company. However, if their lawsuit is successful, the resulting spike could be profitable for experienced momentum traders.

Acasti Pharma Inc. (NASDAQ: ACST)

Heart disease is America’s #1 killer. On average, more than 665,000 succumb – that’s more than America’s COVID death toll, every single year.

As such, there is a healthy market for drugs that address the causes of heart disease, like high triglycerides. That’s the niche that Acasti Pharma is operating in. Their angle? Creating omega-3 based pharmaceuticals derived from krill oil. Recently, this firm managed to get two of these drugs to phase III trials. Sadly, both failed to meet their primary endpoint.

However, the fact they got that far shows they’re getting close. To get across the finish line, Acasti just acquired Grace Therapeutics. In this deal, they’ve acquired Grace’s unique drug delivery system. Is this the missing piece ACST needs? Perhaps – with a share price of 0.60, it won’t cost you much to bank on their future success.

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)

Not only is it devastating, but it’s also lonely. When you or someone you love is diagnosed with a rare disorder, not only do you have to grapple with symptoms, but with a lack of societal awareness. But every once in a while, a pharmaceutical company comes up with treatments for these unknown diseases.

Catalyst Pharmaceuticals is one of those firms. Over the past decade, they successfully brought Firdapse, a drug used to treat Lambert–Eaton myasthenic syndrome (LEMS), through the clinical trial process.

Earlier this year, CPRX rallied on the news that Catalyst Pharmaceuticals was buying back its stock. But, that isn’t all that’s going on within their walls – they are currently running another phase III trial on Firdapse.

This time, they are attempting to determine whether this drug is also effective as a treatment for MuSK-positive myasthenia gravis. They are also planning further Firdapse trials on other rare neuromuscular disorders.

Currently, CPRX is trading around 5.79 – a 64% increase YTD. So far, Firdapse has proven itself to be an effective neuromuscular drug. But if their phase III trials are successful, the news could send CPRX well over 10.00.

Health & Wealth: Name a More Iconic Duo

Most gravely ill people would give anything to restore their health. Because of this, the health industry will always be a robust sector. Find plays that address real needs, and it won’t be long before you find a winner.

Comments

Leave a reply

Your email address will not be published. Required fields are marked *